Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Dow
Moodys
Express Scripts

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR PULMICORT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pulmicort

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000575 ↗ Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) Completed CAMP Steering Committee Phase 3 1991-09-01 The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗ Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1991-09-01 The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗ Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) Completed Johns Hopkins Bloomberg School of Public Health Phase 3 1991-09-01 The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00005880 ↗ Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia Completed National Cancer Institute (NCI) Phase 2 2000-07-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of budesonide may be an effective way to prevent bronchial dysplasia. PURPOSE: Randomized double-blinded phase II trial to determine the effectiveness of budesonide in treating former or current smokers who have bronchial dysplasia.
NCT00005880 ↗ Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia Completed British Columbia Cancer Agency Phase 2 2000-07-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of budesonide may be an effective way to prevent bronchial dysplasia. PURPOSE: Randomized double-blinded phase II trial to determine the effectiveness of budesonide in treating former or current smokers who have bronchial dysplasia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pulmicort

Condition Name

Condition Name for Pulmicort
Intervention Trials
Asthma 42
Chronic Obstructive Pulmonary Disease 4
Respiratory Distress Syndrome 4
Chronic Rhinosinusitis (Diagnosis) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pulmicort
Intervention Trials
Asthma 45
Lung Diseases 9
Pulmonary Disease, Chronic Obstructive 6
Respiratory Distress Syndrome, Newborn 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pulmicort

Trials by Country

Trials by Country for Pulmicort
Location Trials
United States 49
Canada 23
Japan 21
China 21
United Kingdom 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pulmicort
Location Trials
California 5
North Carolina 5
New York 4
Arizona 4
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pulmicort

Clinical Trial Phase

Clinical Trial Phase for Pulmicort
Clinical Trial Phase Trials
Phase 4 29
Phase 3 20
Phase 2/Phase 3 3
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pulmicort
Clinical Trial Phase Trials
Completed 51
Unknown status 12
Withdrawn 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pulmicort

Sponsor Name

Sponsor Name for Pulmicort
Sponsor Trials
AstraZeneca 28
St. Paul's Hospital, Canada 4
National Cancer Institute (NCI) 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pulmicort
Sponsor Trials
Other 100
Industry 41
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
AstraZeneca
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.